Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VeraCept IUD for Long-Acting Reversible Contraception
NCT02446821Phase 2Completed
- Sponsor
- Sebela Pharmaceuticals
- Start
- Jun 2015
- Primary completion
- May 2017
- Modality
- Device-based Delivery, DNA Intercalators/Alkylators, Covalent Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of miudella in pregnancy, sponsored by Sebela Pharmaceuticals. Primary endpoint: Pearl Index at 12 months. Started Jun 2015; status: completed.
02
Drugs
miudella
03
Conditions
pregnancy
Beyond the preview
Go deeper on NCT02446821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02446821.